PUBLISHER: Grand View Research | PRODUCT CODE: 1679569
PUBLISHER: Grand View Research | PRODUCT CODE: 1679569
The global ophthalmic eye dropper market size is anticipated to reach USD 20.02 billion in 2030 and is anticipated to grow at a CAGR of 6.1% from 2025 to 2030. The rising prevalence of eye disorders such as glaucoma, age-related macular degeneration, and eye syndrome among the aging population worldwide has surged the demand for efficient treatments delivered through eye droppers. Moreover, advancements in drug delivery technologies and the introduction of preservative-free eye drops have notably improved patient adherence to treatment regimens. For instance, preservative-free drops are considered safer and preferred by individuals with dry eyes, thus allowing more frequent use.
The rise in eye conditions such as cataracts, glaucoma, dry eye syndrome, and allergies has significantly bolstered the demand for ophthalmic eye drops. For instance, as reported by the National Glaucoma Research, over 3 million Americans live with glaucoma, out of which 2.7 million are affected by the prevalent open-angle glaucoma among those aged 40 and older. This surge in prevalence aligns with the aging global population, contributing to the increasing occurrence of these conditions. Consequently, there's a pressing necessity for effective treatments like eye drops to address these escalating eye health challenges.
The increased awareness about maintaining optimal eye health and regular eye check-ups has improved the demand for ophthalmic eye drops. This proactive approach helps treat ophthalmic issues quicker which allows eye care providers and eye drops manufacturing companies to assist. For instance, companies like Alcon and Bausch + Lomb have made special eye drops for different eye problems, thereby fueling the market growth.